NRx Pharmaceuticals (NASDAQ:NRXP) Shares Up 0.7% – What’s Next?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares were up 0.7% during trading on Friday . The company traded as high as $4.39 and last traded at $4.27. Approximately 424,182 shares traded hands during trading, a decline of 50% from the average daily volume of 856,493 shares. The stock had previously closed at $4.24.

Analyst Ratings Changes

Several research analysts have recently weighed in on NRXP shares. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, April 27th. D. Boral Capital restated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, NRx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $38.25.

NRx Pharmaceuticals Stock Performance

The stock’s 50 day moving average price is $3.85 and its 200-day moving average price is $2.79. The company has a market cap of $154.70 million, a PE ratio of -3.92 and a beta of 2.19.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. On average, analysts anticipate that NRx Pharmaceuticals, Inc. will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the period. Vanguard Group Inc. grew its position in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Two Sigma Investments LP increased its stake in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. One Wealth Management Investment & Advisory Services LLC increased its stake in NRx Pharmaceuticals by 35.3% in the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares during the period. Finally, Sjbenen Advisory LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.